FH and renal cell carcinoma: The biomarkers could also distinguish FH-MT from FH-WT RCC (suc-cys: ROCAUC = 0.980; suc-ado: ROCAUC = 0.923, Figure 8C), suggesting that these biomarkers can be used for both routine screening of carriers of the germline FH mutant (the prevalence of FH mutations in the population is estimated to be 1 in 1,000) (40) and to perform differential diagnosis of patients with RCC.